Cystic Fibrosis
Study Outline
The study aims to evaluate the safety and efficacy of VX-121/tezacaftor/deutivacaftor in cystic fibrosis patients.
To find out if this trial is suitable for you please register below or contact our Clinical Trials Team at admin@resphealth.uwa.edu.au or phone 6151 0888.
Eligibility & Requirements
- Aged 18 or over with a diagnosis of cystic fibrosis
What's Involved
- The total study duration is approximately 64 weeks.
- It involves 13 visits to the Institute for Respiratory Health at the QEII Medical Centre in Nedlands and 6 phone call follow-ups.
Principal Investigator
Dr Siobhain Mulrennan
This Clinical Trial is currently Closed
Please register your interest for future clinical trials and we will contact you when a suitable trial becomes available.
Current Clinical Trials